Temozolomide and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Temozolomide (temozolomide), especially for people who are female, 50-59 old, also take Methylprednisolone, and have Aspergillosis.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Temozolomide. It is created by eHealthMe based on reports of 16,598 people who have side effects when taking Temozolomide from the FDA, and is updated regularly.

What is Temozolomide?

Temozolomide has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 16,644 Temozolomide users. Check the latest studies of Temozolomide.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 593 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

On Jul, 19, 2026

16,598 people reported to have side effects when taking Temozolomide.
Among them, 12 people (0.07%) have Progressive multifocal leukoencephalopathy.

Could Temozolomide cause Progressive multifocal leukoencephalopathy?

Among these 12 people:

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Temozolomide? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Temozolomide? *

What are other drugs people take besides Temozolomide? *

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Neurological Decompensation (inability of brain to maintain proper function): 3 people, 25.00%
Jc Virus Infection: 2 people, 16.67%
Large Intestine Perforation (hole in large intestine): 2 people, 16.67%
Infection: 1 person, 8.33%
Bone Marrow Failure: 1 person, 8.33%
Cd4 Lymphocytes Decreased: 1 person, 8.33%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 1 person, 8.33%
Confusional State: 1 person, 8.33%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 8.33%
Fatigue (feeling of tiredness): 1 person, 8.33%

What are the existing conditions these people have? *

Systemic Mycosis (fungal infections of the body): 1 person, 8.33%
Brain Neoplasm Malignant (brain cancer tumour): 1 person, 8.33%
Aspergillosis (an infection caused by a fungus called aspergillus): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Temozolomide and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temozolomide:

Temozolomide (16,644 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Temozolomide

Expand to all the drugs that have ingredients of temozolomide:

Progressive multifocal leukoencephalopathy and drugs with ingredients of temozolomide

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Temozolomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (593 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on temozolomide (the active ingredients of Temozolomide) and Temozolomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.